Clinical significance of serum triglyceride elevation at early stage of acute biliary pancreatitis

Long Cheng†, Zhulin Luo†, Ke Xiang†, Jiandong Ren2, Zhu Huang1, Lijun Tang1* and Fuzhou Tian1*

Abstract

Background: Pancreatitis induced by hypertriglyceridemia (HTG) has gained much attention. However, very limited numbers of studies have focused on the clinical significance of TG elevation in non-HTG induced pancreatitis, such as acute biliary pancreatitis (ABP). This study aimed to study the clinical significances of triglyceride (TG) elevation in patients with ABP.

Methods: We retrospectively analyzed a total of 426 ABP cases in our research center. According to the highest TG level within 72 h of disease onset, the patients were divided into a normal TG group and an elevated TG group. We analyzed the differences between the two groups of patients in aspects such as general information, disease severity, APACHE II (acute physiology and chronic health evaluation II) and Ranson scores, inflammatory cytokines, complications and prognosis.

Results: Compared with the normal TG group, patients in the elevated TG group showed a significantly higher body mass index and were significantly younger. TG elevation at the early stage of ABP was associated with higher risk of severe pancreatitis and organ failures, especially respiratory failure. For patients with severe pancreatitis, those with elevated TG levels were more likely to have a larger area of necrosis, and higher incidence of pancreatic abscess as well as higher mortality (17.78% versus 9.80%, P < 0.05).

Conclusions: In ABP patients, TG elevation might participate in the aggravation of pancreatitis and the occurrence of systemic or local complications. Thus, the TG level may serve as an important indicator to determine the prognosis of patients with ABP.

Keywords: Acute pancreatitis, Biliary pancreatitis, Hypertriglyceridemia, Triglyceride

Background

Acute pancreatitis (AP) is a life-threatening inflammatory disease involving the pancreas as well as peripancreatic and even distant organs [1]. The main causes of AP include biliary tract disease, alcohol abuse, congenital anomaly, drugs, etc. [2]. In recent years, the relationship between hypertriglyceridemia (HTG) and AP has received widespread attention from scholars, and it is generally believed that blood triglyceride (TG) levels greater than 11.3 mmol/L can directly induce AP [3,4]. However, HTG-induced AP is uncommon, accounting for only 1-4% of AP cases. On the other hand, HTG is commonly present at the early stage of non-HTG-induced AP, such as acute biliary pancreatitis (ABP), and its clinical significance remains unclear.

It has been reported that more than 50% of non-HTG-induced AP patients demonstrate mild-to-moderate TG elevation [5]. However, the relationship between the elevated TG level and severity of non-HTG-induced AP is not well documented. Some studies reported that when non-HTG-induced AP was accompanied by TG elevation, the disease course of AP shows a trend for aggravation; in particular, if the serum TG level is reduced under 5.65 mmol/L, the disease condition will be gradually stabilized and improved [6-8]. However, some other studies showed that an increased TG level might just represent a symptom associated with AP, and there is no significant relationship between an elevated TG level and the severity and prognosis of AP patients [9]. This discrepancy may be due to the fact that the AP cases included in these studies...
were induced by different causes, and HTG might play different roles in AP cases induced by different causes. Therefore, investigating the clinical significance of an elevated TG level in AP induced by a single homogeneous cause could more accurately illustrate the effects of mild-to-moderate HTG on the severity and prognosis of AP patients. As acute biliary pancreatitis (ABP) remains the main type of AP in China and many other countries, the current study focused on the clinical significance of HTG in ABP patients.

Methods

Patients

Patient selection

This study retrospectively analyzed 426 ABP cases that were treated in our hospital. The diagnosis and classification of the severity of AP were performed according to the 2012 revision of the Atlanta Classification [10]. The diagnosis of ABP was based on the standards proposed in the literature with the following minor amendments [11]: 1) confirmed diagnosis of AP; 2) no history of hyperlipidemia or alcohol abuse; 3) abdominal ultrasonography (AUS), computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), and endoscopic ultrasound (EUS) detection of gallstones or biliary sludge, or laboratory tests showing two of the following items: ALT >75U/L, ALP >125 U/L, and TBIL >2.3 mg/dl. This study was performed according to the principles of the Declaration of Helsinki (modified 2000) and was approved by the ethics committee of Chengdu Military General Hospital (No. 2013037).

Treatment protocols

At the outset, all patients were treated in a conservative manner, with fluid resuscitation and antibiotics, as described in the literature [12,13]. Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST) were performed in patients with jaundice and cholangitis. Percutaneous catheter drainage (PCD) were carried out to eliminate the debris and collections in the (peri)pancreas, similar to other reports [14]. The number and size of the catheters were determined by the size, viscosity, and location of the debris and collections. In accordance with widely accepted consensus [15], if there was no clinical improvement or if ongoing necrosis with bowel complications was present, open necrosectomy with closed lesser-sac drainage and postoperative lavage was performed.

Methods

Group division

According to the highest TG level within 72 h of disease onset, the patients were divided into a normal TG group (<1.88 mmol/L) and an elevated TG group (≥1.88 mmol/L).

Data collection

In addition to the collection of general information including sex, age, body mass index (index), etc., we specially analyzed differences between the normal TG group and the elevated TG group in aspects such as pancreatitis severity score, incidence of systemic complications, incidence of local complications, mortality, days in hospital and intensive care unit and care cost. Differences in levels of inflammatory cytokines within 72 h of disease onset—C-reactive protein (CRP), interleukin 6 (IL-6), IL-10, tumor necrosis factor-alpha (TNF-α)—between the two groups were also analyzed. Initial contrast-enhanced computed tomography was performed within the first week of the onset of disease and repeated depending on the indication. The images obtained were double-checked by two experienced radiologists. Meanwhile, extent of necrosis were measured and classified into three grades, <30%, 30-50% and >50%, according to Balthazar classification. Acute physiology and chronic health evaluation II (APACHE II) score and CTSI were calculated for each patient at the time of admission and serially calculated before and after each type of intervention.

Definition and criteria

The classification of AP severity was based on the 2012 revision of the Atlanta Classification, and the Ranson score and APACHE II (acute physiology and chronic health evaluation II) score were calculated within 24 ~ 48 h after patient admission.

The diagnostic criteria for systemic complications of AP were as follows: shock, with systolic blood pressure ≤80 mmHg and a duration of 15 min; respiratory failure, with PaO2 ≤ 60 mmHg; renal failure, with serum creatinine >176.8 μmol/L; coagulation disorders, with prothrombin time (PT) less than 70% that of normal people and/or partial thromboplastin time (PTT) >45 s; sepsis, with a body temperature (T) > 38.5°C, white blood cell (WBC) count >6.0 × 10⁹/L, base excess ≤ 4 μmol/L, a duration of 48 h, and positive blood/ aspirate bacterial culture; systemic response syndrome, with T >38.5°C or <36°C, WBC count >12.0 × 10⁹/L or <4.0 × 10⁹/L, pulse >90 beats/min, and respiratory rate >20 breaths/min or PCO2 < 32 mmHg; upper gastrointestinal bleeding; and pancreatic encephalopathy. Local complications of AP included pancreatic necrosis, inanimate pancreatic tissue, or peripancreatic fat as revealed by enhanced CT and pancreatic pseudocyst, with liquid accumulation wrapped in a complete and non-epithelial envelope and enclosed pancreatic secretions, granulation tissue, and fibrous tissue.
Statistical methods
The statistical analysis was carried out using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL). Normality of data was determined by Kolmogorov–Smirnov tests of normality. Data were expressed as mean ± standard deviation for normally distributed data and median and interquartile range for non-normally distributed data. For normally distributed data, variables were compared using Student’s t test for two groups. For skewed data, the Mann–Whitney test was used. Qualitative or categorical variables were described as frequencies and proportions. Proportional variables were compared using the χ² test or Fisher’s exact test. All statistical tests were two-tailed and performed at a significance level of P < 0.05.

Results
Comparison of general information of patients
There were 426 ABP cases included, of which 289 (67.84%) were assigned to the normal TG group and 137 (32.16%) to the elevated TG group. The mean levels of TG in the two groups were 1.21 mmol/L and 6.52 mmol/L, respectively. This cohort included 188 male and 238 female patients, and the male/female ratio of the elevated TG group was significantly higher than that of the normal TG group (72/65 versus 116/173, p < 0.05). In addition, the age of the patients in the elevated TG group was significantly lower than that in the normal TG group (46.35 ± 7.26 versus 54.89 ± 7.84, p < 0.05), while the body mass index (BMI) of the elevated TG group was significantly higher than that of the normal TG group (28.35 ± 5.13 versus 22.57 ± 4.42, p < 0.01), Table 1. Meanwhile, the frequencies of manifestation of cholangitis between the two groups were not significantly different, 22.15% (64/289) versus 23.36% (32/137). These results showed that younger male ABP patients with a higher BMI were more likely to be complicated with TG elevation.

Relationship between TG level and ABP severity
The total incidence rate of moderately severe acute pancreatitis (MSAP) and severe acute pancreatitis (SAP) in this study group was 22.54% (96/426); in particular, SAP and MSAP patients accounted for 32.85% (45/137) of the cases in elevated TG group, and this rate was significantly higher than that in the normal TG group (p < 0.05). Laboratory detection showed that the CRP level in elevated TG group was remarkably higher than that in normal TG group (p < 0.05). Meanwhile, patients in the elevated TG group had APACHE II scores and Ranson scores that were significantly higher than those of patients in the normal TG group (p values were <0.01 and <0.05, respectively), Table 2. Correlation analysis showed that TG levels and APACHE II scores were significantly correlated (p < 0.05, R = 0.665) in patients in the elevated TG group, whereas TG levels were not significantly correlated with the Ranson score. These results suggest that elevated TG levels in the early phase of ABP may be involved in the progress of the disease.

Table 1 The characteristics of ABP patients enrolled in this study

| Characteristic                                      | Normal TG group | Elevated TG group | P value |
|-----------------------------------------------------|-----------------|-------------------|---------|
| Number of patients                                  | 289             | 137               |         |
| Demographic data                                    |                 |                   |         |
| Age (mean ± SD)                                     | 54.89 ± 7.84    | 46.35 ± 7.26      | 0.011*  |
| Male/female                                         | 116/173         | 72/65             | 0.027*  |
| BMI                                                 | 22.57 ± 4.42    | 28.35 ± 5.13      | 0.001*  |
| Referral after onset of symptoms (hours) (mean ± SD) | 26.8 ± 16.8     | 24.5 ± 15.2       | 0.402   |
| TG level (mmol/L)                                   | 1.21 ± 0.56     | 6.52 ± 1.52       | 0.001*  |
| Manifestation of cholangitis (%)                    | 22.15% (64/289) | 23.36% (32/137)   | 0.435   |
| Medical economics (median ± interquartile range)    |                 |                   |         |
| Days in hospital                                    | 34.7 ± 16.42    | 39.5 ± 18.54      | 0.375   |
| Days in intensive care unit (ICU)                   | 5.2 ± 2.36      | 6.4 ± 3.46        | 0.562   |
| Total cost during hospitalization (Dollars)          | 5646.1 ± 1432.32| 6103.2 ± 2140.29  | 0.781   |

TG, triglyceride; BMI, body mass index. *Significant difference.
failure, coagulation disorders, and other types of organ failure (p > 0.05). These results suggest that ABP patients with elevated TG levels are more likely to develop organ failure, particularly respiratory failure.

**Effect of TG elevation on the development of local complications in patients with ABP**

Among patients with moderate-severe degrees of severe ABP, 55.56% of patients with elevated TG levels had pancreatic necrosis, and 50.98% of patients with normal TG had pancreatic necrosis, with no significant difference between these two groups. However, patients with elevated TG levels showed significantly higher probabilities of developing necrosis over a relatively large area (with a necrotic area greater than 30%) and a higher incidence of pancreatic abscess compared to patients with normal TG levels, Table 4. For patients with moderate-severe degrees of severe ABP, there was no significant difference in the incidence rates of pseudocysts between patients with elevated TG and patients with normal TG levels. These results suggest that although TG elevation did not increase the total incidence of pancreatic necrosis in ABP patients, TG elevation may increase the scope and extent of pancreatic necrosis once necrosis occurs.

**Association of TG level with treatments and prognosis of ABP patients**

All mild ABP patients were treated in a conservative manner and were discharged after rehabilitation. There were 41.87% of mild ABP patients (139/332) underwent ERCP/EST, and no significant difference was observed between normal TG group and elevated TG group. Besides ERCP/EST, PC and open necrosectomy were also performed in some of patients with moderate or severe ABP. For patients with MSAP/SAP, although the frequencies of ERCP/EST were not significantly different between normal TG group and elevated TG group (47.06% (24/51) versus 46.67% (21/45)), more patients in elevated TG group underwent PCD and open necrosectomy, Table 5. The mortality rate of severe ABP patients with elevated TG was 17.78% (8/45), whereas that of severe ABP patients with normal serum TG was 9.80% (5/51); the difference between the two groups was significant (p < 0.05). The patients were followed for 1 year, and we found no significant differences in the recurrence rate and life quality of patients after discharge. These results showed that TG elevation may be a manifestation indicating poor prognosis in patients with ABP.

**Discussion**

In recent years, the relationship between HTG and AP has received widespread attention from scholars, and it

| Items                          | Normal TG group | Elevated TG group | P value |
|-------------------------------|-----------------|-------------------|---------|
| Number of patients            | 289             | 137               |         |
| Severity classification       |                 |                   |         |
| MAP                           | 238 (82.35%)    | 94 (68.61%)       | 0.157   |
| MSAP                          | 32 (11.07%)     | 28 (20.44%)       | 0.021*  |
| SAP                           | 19 (6.57%)      | 17 (12.41%)       | 0.015*  |

**Lab parameters**

| Cre:ACTION protein (CRP) (mg/L) | 36.2 ± 15.33 | 61.2 ± 18.41 | 0.038* |
| IL-6 (pg/L)                    | 54.5 ± 20.41 | 62.6 ± 22.42 | 0.241  |
| IL-10 (pg/L)                   | 30.6 ± 17.48 | 35.1 ± 18.59 | 0.672  |
| TNF-α (pg/L)                   | 8.2 ± 3.53   | 9.8 ± 3.77   | 0.521  |

**Severity scores**

| APACHIIIC score (mean ± SD)    | 6.26 ± 3.48 | 10.11 ± 3.62 | 0.007* |
| Ranson score (mean ± SD)       | 1.68 ± 0.79 | 2.34 ± 0.93  | 0.042* |
| Marshall score (mean ± SD)     | 2.1 ± 0.57  | 2.6 ± 0.68   | 0.142  |

**Table 3 Incidence of organ failure in MSAP or SAP patients**

| Items                          | Normal TG group | Elevated TG group | P value |
|-------------------------------|-----------------|-------------------|---------|
| Number of patients            | 51              | 45                |         |
| Total organ failure           |                 |                   |         |
| Single                        | 17 (33.33%)     | 21 (46.67%)       | 0.030*  |
| Multiple                      | 11 (21.57%)     | 15 (33.33%)       | 0.047*  |
| Respiratory                   | 6 (11.76%)      | 6 (13.33%)        | 0.761   |
| Circulation                   | 7 (13.73%)      | 13 (28.89%)       | 0.022*  |
| Kidney                        | 5 (9.80%)       | 3 (6.67%)         | 0.535   |
| Coagulation                   | 6 (11.76%)      | 5 (11.11%)        | 0.882   |
| Other organ or system         | 4 (7.84%)       | 3 (6.67%)         | 0.682   |

**Table 4 Occurrence of local complications in MSAP or SAP patients**

| Items                          | Normal TG group | Elevated TG group | P value |
|-------------------------------|-----------------|-------------------|---------|
| Number of patients            | 51              | 45                |         |
| Incidence of necrosis         | 34 (66.67%)     | 36 (80.00%)       | 0.253   |
| Maximum extent of necrosis   |                 |                   |         |
| Less than 30%                 | 18 (35.29%)     | 12 (26.67%)       | 0.137   |
| 30% ~ 50%                     | 10 (19.61%)     | 15 (33.33%)       | 0.027*  |
| More than 50%                 | 6 (11.76%)      | 9 (20.00%)        | 0.001*  |
| Pancreatic abcess             | 4 (7.84%)       | 8 (17.78%)        | 0.001*  |
| Pseudocyst                    | 6 (11.76%)      | 5 (11.11%)        | 0.683   |

*Significant difference.
is generally believed that a serum TG level >11.3 mmol/L can directly induce AP. However, despite the increasing incidence of AP induced by HTG, this type of AP is not the major type observed in clinical practice. The more common clinical situation is that non-HTG-induced AP patients were complicated with TG elevation, and it has been reported in the literature that approximately 50% of non-HTG-induced AP patients demonstrate mild-moderate TG elevation. However, there have been only limited numbers of studies on the significance of TG elevation in non-HTG-induced pancreatitis, such as acute biliary pancreatitis (ABP), and the results were inconsistent.

It also remains controversial whether TG elevation is an associated etiological factor or a concomitant symptom in non-HTG-induced AP patients. In alcoholic pancreatitis, alcohol can directly affect the metabolism of TG, causing elevated TG levels, and is therefore directly involved in the occurrence of pancreatitis. Thus, an elevated TG level can be seen as an associated etiological factor of alcoholic pancreatitis [16], whereas it may be considered as concurrent symptom of biliary pancreatitis [17]. In addition, the relationships between TG elevation and the severity and prognosis of AP, as reported in the literature, are also inconsistent. For example, studies have reported that when AP induced by non-HTG causes is complicated with TG elevation, the disease course of AP shows a trend for aggravation [7,8]. However, other studies show that an increased TG level may only represent a symptom associated with AP, as there is no significant relationship between TG level and the severity and prognosis of AP patients [9]. The presence of these controversies is likely due to the analysis of different compositions of AP patient, including patients with biliary AP, alcoholic AP, cryptogenic AP, and AP due to other factors, as HTG is known to play different roles in AP caused by different factors.

Therefore, the study of the clinical significance of an elevated TG level in AP due to a single etiological factor could accurately illustrate the effects of mild-moderate HTG on AP disease condition and prognosis. Because biliary tract disease is a major cause of AP in China and other Eastern countries, we chose to study the effects of TG elevation on the disease condition and prognosis of patients with ABP. When selecting cases, we excluded patients with a history of hyperlipidemia and alcoholism, aiming to exclude cases with elevated TG levels before the onset of pancreatitis. During the occurrence of AP, due to the body’s stress response, serum catecholamine and glucagon levels, as well as lipase activity, are increased, leading to accelerated break down of fat tissue and the subsequent release of TG and increase in serum lipid concentrations [18,19]. In this study group, the incidence of SAP in APB patients associated with elevated TG was significantly higher compared to that in patients without elevated TG; in addition, ABP patients with elevated TG levels also showed more severe pancreatic necrosis. These results may be due to the fact that elevated TG might lead to increased blood viscosity, which further promotes blood circulation disorders of the pancreas. In addition, large quantities of free fatty acids released from TG breakdown damage the pancreatic acinar cells and capillaries, leading to a higher likelihood of SAP [20,21]. Furthermore, this result might also be related to the participation of cholecystokinin, as some studies have shown that in the presence of TG elevation, free fatty acids produced in the body can strengthen the stimulation of cholecystokinin on the excretion function of pancreatic acinar cells, which subsequently activates the endoplasmic reticulum stress phenomenon and thereby damages pancreatic acinar cells [22].

This study also found that ABP patients with elevated TG levels were more prone to organ failure, particularly respiratory failure. In the AP disease course, respiratory complications primarily include hypoxemia, acute respiratory distress syndrome, atelectasis, and pleural effusion. Respiratory failure is largely due to the large number of toxic cytokines produced during the AP disease course, mainly including platelet-activating factor, TNF-α, IL-1, IL-6, IL-8, NO, P substance, and macrophage-secreted cytokines, which can cause systemic inflammatory response syndrome and respiratory dysfunction. The reason why ABP patients with elevated TG levels were more likely to experience respiratory failure is related to the functions of free fatty acids. In the presence of elevated TG, serum TG is broken down under the action of lipoprotein lipase in the lung, leading to the production of large quantities of free fatty acids. Subsequently, free fatty acids dissociate from albumin in the blood, enter the alveolar capillary membrane, and destruct the pulmonary blood microcirculation, leading to respiratory failure [23,24].

It remains unclear why some ABP patients show elevated TG levels while others have normal TG levels, and why the degree of elevated TG varies among patients. We believe that this difference may be related to a number of

---

**Table 5 Treatment and prognosis for MSAP or SAP patients**

| Items                  | Normal TG group (%) | Elevated TG group (%) | P value |
|------------------------|---------------------|-----------------------|---------|
| Number of patients     | 51                  | 45                    |         |
| ERCP or EST            | 24 (47.06%)         | 21 (46.67%)           | 0.566   |
| PCD                    | 20 (39.12%)         | 27 (60.00%)           | 0.033*  |
| Open necrosectomy      | 3 (5.88%)           | 9 (13.33%)            | 0.037*  |
| Mortality              | 5 (9.80%)           | 8 (17.78%)            | 0.011*  |
| Recurrence rate        | 10 (19.61%)         | 11 (24.44%)           | 0.372   |

ERCP, Endoscopic retrograde cholangiopancreatography; and EST, endoscopic sphincterotomy; PCD, Percutaneous catheter drainage. *Significant difference.
factors. First, the local or whole body fat distribution of patients may be associated with elevated TG levels and the degree of such elevation. When the body has high levels of fat, under the same level of stress and level of lipase activity, the amount of involved fat tissue is increased, and the amount of TG release is increased. In the present study, the BMI of ABP patients with elevated TG levels was significantly higher than that in patients with normal TG levels. Indeed, previous studies have shown that obesity is closely associated with AP aggravation, and some scholars have suggested that obesity should be considered an independent risk factor of AP aggravation, which is consistent with the results of this study. In addition, in recent years, some scholars have found that genetic polymorphisms are associated with the pathogenesis of AP with HTG [25]. For example, Chang and his colleagues [26] first reported that in HTG-induced AP patients, lipoprotein lipase gene mutation was significantly increased, and the probability of AP was 77.8% in patients with hyperlipidemia caused by the mutation in this gene. In short, there may be a mutually reinforcing cycle between elevated TG levels and pancreatitis, such that the occurrence of pancreatitis leads to elevated TG levels, which further increase the severity of pancreatitis. This cycle may represent another important vicious cycles in AP pathogenesis, and timely blockade of this cycle may hold important significance for reducing the degree of AP aggravation and improving the efficacy and prognosis for patients with SAP.

The general treatment protocol of ABP was similar to AP induced by other causes. At the outset, all patients were treated in a conservative manner, and subsequently so-called step-up approach was carried out [27,28]. Meanwhile, ERCP and EST were selectively performed in some ABP patients, especially for patients with jaundice and cholangitis. However, there were still controversies on the indications and outcomes of ERCP and EST in ABP treatment [29,30]. In the current study, no significant difference of the frequencies of ERCP/EST was observed between normal TG group and elevated TG group. For patients with MSAP/SAP, the frequencies of ERCP/EST were also not significantly different between normal TG group and elevated TG group, but more patients in elevated TG group underwent PCD and open necrosectomy. These results indicated that the ABP patients with TG elevation might be liable to undergo PCD and open necrosectomy. However, as the patients were divided into two groups according to the highest TG level within 72 h of disease onset, we presumed that the raised TG level might be responsible for the liability of PCD and open necrosectomy.

Conclusions
In summary, when ABP is accompanied with TG elevation, the risks of SAP and organ failure (especially respiratory failure) are significantly higher compared to patients with normal TG levels. In particular, elevated TG levels and pancreatitis may form a mutually reinforcing cycle, and timely implementations of measures to block this vicious cycle may hold important significance for reducing the rate of AP aggravation and improving the treatment effects and prognosis of SAP patients. Nevertheless, further research is needed to reveal the pathophysiological mechanisms for why elevated TG levels are present in AP patients, as well as the mechanism by which elevated TG cause injury to specific tissues and organs.

Abbreviations
AP: Acute pancreatitis; TG: Triglyceride; ABP: Acute biliary pancreatitis; HTG: Hypertriglyceridemia; APACHE II: Acute physiology and chronic health evaluation II; AUS: Abdominal ultrasonography; CT: Computed tomography; MRCP: Magnetic resonance cholangiopancreatography; EUS: Endoscopic ultrasound.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
LC contributed to the design of the study and direction of its implementation. FZT and LJT conceived and designed the experiments and supervision of the field activities. LC and ZLL carried out the prepared the Materials of patient and prepared the literature review as well as the Discussion sections of the text. JDR, KX and ZH conducted the data analysis. All authors read and approved the final version of the manuscript.

Acknowledgements
This work was supported by the National Scientific Foundation Committee of China (No. 81300280).

Author details
1Department of General Surgery, Chengdu Military General Hospital, Jinniu District, Chengdu, Sichuan Province, PR China, 610083. 2Department of Pharmacy, Chengdu Military General Hospital, Chengdu, Sichuan Province, People’s Republic of China.

Received: 25 August 2014 Accepted: 6 February 2015
Published online: 14 February 2015

References
1. Wu BU, Conwell DL. Update in acute pancreatitis. Curr Gastroenterol Rep. 2010;12:83–90.
2. Waldthaler A, Schurte K, Malfertheiner P. Causes and mechanisms in acute pancreatitis. Dig Dis. 2010;28:364–72.
3. Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Internal Med. 2013;173:162–4.
4. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48:195–203.
5. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20:497–504.
6. Lindberg DA. Acute pancreatitis and hypertriglyceridemia. Gastroenterol Nurs. 2009;22:75–82.
7. Deng LH, Xue P, Xia Q, Yang XN, Wan MH. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol. 2008;14:4558–61.
8. Anderson F, Thomson SR, Clarke DL, Buccinazzia I. Dyslipidaemic pancreatitis clinical assessment and analysis of disease severity and outcomes. Pancreatology. 2009;9:252–7.
9. Preis D. Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. Expert Rev Gastroenterol Hepatol. 2013;7:193–5.
10. Banks PA, Bollen TL, Dervenis C, Goosen KG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–11.
11. van Geenen EJ, van der Peet DL, Bhagirath P, Mulder CJ, Bruno MJ. Etiology and diagnosis of acute biliary pancreatitis. Nat Rev Gastroenterol Hepatol. 2010;7:495–502.

12. Babu RY, Gupta R, Kang M, Bhasin DK, Rana SS, Singh R. Predictors of surgery in patients with severe acute pancreatitis managed by the step-up approach. Ann Surg. 2013;257:737–50.

13. van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362:1491–502.

14. Baudin G, Chassang M, Gelsi E, Novellas S, Bernardin G, Hebuterne X, et al. CT-guided percutaneous catheter drainage of acute infectious necrotizing pancreatitis: assessment of effectiveness and safety. AJR Am J Roentgenol. 2012;199:192–9.

15. Bausch D, Wellner U, Kahl S, Kuesters S, Richter-Schrag HJ, et al. Minimally invasive operations for acute necrotizing pancreatitis: comparison of minimally invasive retroperitoneal necrosectomy with endoscopic transgastric necrosectomy. Surgery. 2012;152:5128–34.

16. Klop B, Rego AT, Cabezas MC. Alcohol and plasma triglycerides. Curr Opin Lipidol. 2013;24:321–6.

17. Stefanutti C, Labbadia G, Morozzi C. Severe hypertriglyceridemia-related acute pancreatitis. Ther Apher Dial. 2013;17:130–7.

18. Murad MH, Hazem A, Coto-Yglesias F. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12:2.

19. Bruzzolli JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. J Clin Lipid. 2012;6:409–12.

20. Kota SK, Krishna SV, Lakhtakia S, Modi KD. Metabolic pancreatitis: Etiopathogenesis and management. Indian J Endocrinol Metab. 2013;7:799–805.

21. Yang F, Wang Y, Sternfeld L, Rodriguez JA, Ross C, Hayden MR, et al. The role of free fatty acids, pancreatic lipase and Ca+ signaling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf). 2009;195:13–28.

22. Zeng Y, Wang X, Zhang W, Wu K, Ma J. Hypertriglyceridemia aggravates ER stress and pathogenesis of acute pancreatitis. Hepatogastroenterology. 2012;59:2318–26.

23. Zhou MT, Chen CS, Chen BC, Zhang QY, Andresson R. Acute lung injury and ARDS in acute pancreatitis: mechanisms and potential intervention. World J Gastroenterol. 2010;16:2094–9.

24. Patel AD. Hypertriglyceridemia-induced acute pancreatitis treatment with insulin and heparin. Indian J Endocrinol Metab. 2012;16:671–2.

25. Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37:13–22.

26. Chang YT, Chang MC, Su TC, Liang PC, Su YN, Kuo CY, et al. Lipoprotein lipase mutation S447X associated with pancreatic calcification and steatorrhea in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2009;43:591–6.

27. Zerem E, Imamovic G, Susic A, Haracic B. Step-up approach to infected necrotizing pancreatitis: a 20-year experience of percutaneous drainage in a single centre. Dig Liver Dis. 2011;43:478–83.

28. van Baal MC, van Santvoort HC, Bollen TL, Bakker OJ, Besselink MG, Gooszen HG, et al. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. Br J Surg. 2011;98:18–27.

29. Kuo VC, Tamasky PR. Endoscopic management of acute biliary pancreatitis. Gastrointest Endosc Clin N Am. 2013;23:749–68.

30. van Geenen EJ, van Santvoort HC, Besselink MG, van der Peet DL, van Erpecum KJ, Fockens P, et al. Lack of consensus on the role of endoscopic retrograde cholangiography in acute biliary pancreatitis in published meta-analyses and guidelines: a systematic review. Pancreas. 2013;42:774–80.